Oak Therapeutics

New NIH funding advances Oak's proprietary high-drug-load ODS platform toward scalable manufacturing

Oak Therapeutics, a pioneering early-stage life sciences company, announces the successful development of an innovative Oral Dissolvable Strip (ODS) formulation for the treatment of HIV/AIDS in infants and young children.